# Farsin Yadegardjam

> Farsin Yadegardjam is a startup investor at Phenex Pharmaceuticals (Frankfurt). See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Phenex Pharmaceuticals](https://shizune.co/investors/profile/phenex-pharmaceuticals)
- Location: Frankfurt, Germany
- Last updated: Aug 2026

Farsin Yadegardjam is a partner and shareholder of Co-Investor AG (Zurich / Frankfurt), as well as chief executive of its wholly owned subsidiary, EVP Capital Management AG. He is responsible for the Group's investment portfolio, which invests in medium-sized companies with growth dynamics. Since the year 2000, he has been active in theinvestment business. As an investor, he was involved in a series of successful transactions, including the sale of the Cool Chain Group's assets to the METRO Group (2016), the sale of Signature Diagnostics to Roche (2015) and the Phenex asset deal with Gilead (2014). Nanogate was his first investment in 2001, which is why he has been closely linked to the company since then. In addition to Nanogate, he is currently a member of the supervisory bodies of the companies EUROIMMUN AG (Lübeck), Phenex Pharmaceuticals AG, Schaetti Holding AG (Switzerland), Tranquini GmbH (Austria) and K & K Group AG (Switzerland). Farsin Yadegardjam obtained his PhD in chemical technology at the Technical University of Darmstadt in 1995. He began his professional career at the Boston Consulting Group, where he worked from 1996 to 2000.

## About Phenex Pharmaceuticals

VC Fund · Heidelberg, Germany

Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen.Their company focuses its small-molecule drug discovery expertise in Liver andGastrointestinal disease areas and has now recently entered the field of Cancer Therapy. They not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities. Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules.

4 contacts available at Phenex Pharmaceuticals.

| Name | Title | Profile |
| --- | --- | --- |
| Farsin Yadegardjam | Chairman of the Supervisory Board | https://shizune.co/investors/profile/dr-farsin-yadegardjam |
| Claus Kremoser | Chief Executive Officer | https://shizune.co/investors/profile/dr-claus-kremoser |
| Thomas Hoffmann | Chief Financial Officer | https://shizune.co/investors/profile/thomas-hoffmann-2 |
| Thomas Schlueter | VP Discovery Services | https://shizune.co/investors/profile/dr-thomas-schlueter |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co